Somatostatin receptor ligands and resistance to treatment in pituitary adenomas
Open Access
- 18 March 2014
- journal article
- review article
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 52 (3), R223-R240
- https://doi.org/10.1530/jme-14-0011
Abstract
Somatostatin (SST), an inhibitory polypeptide with two biologically active forms SST14 and SST28, inhibits GH, prolactin (PRL), TSH, and ACTH secretion in the anterior pituitary gland. SST also has an antiproliferative effect inducing cell cycle arrest and apoptosis. Such actions are mediated through five G-protein-coupled somatostatin receptors (SSTR): SSTR1–SSTR5. In GH-secreting adenomas, SSTR2 expression predominates, and somatostatin receptor ligands (SRLs; octreotide and lanreotide) directed to SSTR2 are presently the mainstays of medical therapy. However, about half of patients show incomplete biochemical remission, but the definition of resistanceper seremains controversial. We summarize here the determinants of SRL resistance in acromegaly patients, including clinical, imaging features as well as molecular (mutations, SSTR variants, and polymorphisms), and histopathological (granulation pattern, and proteins and receptor expression) predictors. The role of SSTR5 may explain the partial responsiveness to SRLs in patients with adequate SSTR2 density in the cell membrane. In patients with ACTH-secreting pituitary adenomas, i.e. Cushing's disease (CD), SSTR5 is the most abundant receptor expressed and tumors show low SSTR2 density due to hypercortisolism-induced SSTR2 down-regulation. Clinical studies with pasireotide, a multireceptor-targeted SRL with increased SSTR5 activity, lead to approval of pasireotide for treatment of patients with CD. Other SRL delivery modes (oral octreotide), multireceptor-targeted SRL (somatoprim) or chimeric compounds targeting dopamine D2 receptors and SSTR2 (dopastatin), are briefly discussed.Keywords
This publication has 96 references indexed in Scilit:
- New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapyJournal of Neuro-Oncology, 2013
- Medical management of Cushing’s disease: what is the future?Pituitary, 2012
- Homologous and Heterologous in Vitro Regulation of Pituitary Receptors for Somatostatin, Growth Hormone (GH)-Releasing Hormone, and Ghrelin in a Nonhuman Primate (Papio anubis)Endocrinology, 2012
- Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature reviewPituitary, 2010
- Pituitary somatostatin receptor signalingTrends in Endocrinology & Metabolism, 2010
- Acromegaly pathogenesis and treatmentJCI Insight, 2009
- Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extensionPituitary, 2009
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic reviewPituitary, 2009
- Somatostatin agonists for treatment of acromegalyMolecular and Cellular Endocrinology, 2008
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007